BioNxt Solutions Inc
CNSX:BNXT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BioNxt Solutions Inc
Goodwill
BioNxt Solutions Inc
Goodwill Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Goodwill | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioNxt Solutions Inc
CNSX:BNXT
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Goodwill
$11.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-5%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Goodwill
CA$47.5m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Goodwill
$66.5m
|
CAGR 3-Years
301%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
72%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Goodwill
$19.9m
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Goodwill
CA$90m
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
BioNxt Solutions Inc
Glance View
BioNxt Solutions, Inc. engages in the production, extraction and sale of medical cannabis. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2019-08-06. The firm is focused on drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications. The firm has research and development operations in North America and Europe, with an operational focus in Germany. The firm is also focused on regulatory approval and commercialization of medical products for European markets.
